Suggested remit - To appraise the clinical and cost effectiveness of nintedanib within its marketing authorisation for treating progressive fibrosing interstitial lung disease (PF-ILD).
 
Status In progress
Process STA 2018
ID number 1599

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Boehringer Ingelheim (nintedanib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Action for Pulmonary Fibrosis
  Scleroderma & Raynaud’s UK
Professional groups Association of Respiratory Nurse Specialists
  British Society for Rheumatology
  British Thoracic Society
  Royal College of Physicians
  UK Clinical Pharmacy Association

Commentators

Associated public health groups None
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
04 August 2021 - 25 August 2021 Appraisal consultation
07 July 2021 Committee meeting: 1
05 November 2020 Invitation to participate
04 November 2020 In progress. In progress
06 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
08 November 2019 (14:00) Scoping workshop (Manchester)
23 September 2019 - 21 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
27 August 2019 The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of nintedanib for treating progressive fibrosing interstitial lung disease ID1599. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal. On receiving information from the company that markets nintedanib, NICE has agreed that holding a scoping exercise at this time is not appropriate. Consequently, the scoping workshop arranged for the 13 September 2019 will be cancelled. We apologise for any inconvenience this may cause. The Scoping workshop will be rescheduled to November 2019. If you have any comments or concerns, please contact the project manager for this proposed appraisal Michelle Adhemar via email on michelle.adhemar@nice.org.uk

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance